Patents Assigned to Actavis Group PTC EHF
-
Publication number: 20110171274Abstract: Provided herein is an impurity of fesoterodine, fesoterodine dehydroxy impurity, 2-[(1R)-3-[bis(1-methylethy)amino]-1-phenylpropyl]-4-methylphenyl isobutyrate, and a process for preparing and isolating thereof. Provided further herein is a highly pure fesoterodine or a pharmaceutically acceptable salt thereof substantially free of fesoterodine dehydroxy impurity, process for the preparation thereof, and pharmaceutical compositions comprising highly pure fesoterodine or a pharmaceutically acceptable salt thereof substantially free of dehydroxy impurity. Provided also herein is a pharmaceutical composition comprising solid particles of pure fesoterodine fumarate substantially free of dehydroxy impurity, wherein 90 volume-percent of the particles (D90) have a size of less than about 200 microns.Type: ApplicationFiled: July 21, 2009Publication date: July 14, 2011Applicant: ACTAVIS GROUP PTC EHFInventors: Praveen Kumar Neela, Kishore Charugundla, Udhaya Kumar, Nitin Sharadchandra Pradhan
-
Publication number: 20110142883Abstract: The present invention relates to stable amorphous co-precipitates of atorvastatin pharmaceutically acceptable salts with pharmaceutically acceptable excipients, method for the preparation, pharmaceutical compositions, and method of treating thereof.Type: ApplicationFiled: July 21, 2008Publication date: June 16, 2011Applicant: ACTAVIS GROUP PTC EHFInventors: Girish Dixit, Anil Shahaji Khile, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Publication number: 20110124903Abstract: Provided herein are novel solid state forms of fesoterodine intermediates, (R)-4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzoic acid and (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol, and processes for their preparation thereof. The solid state intermediates are useful for preparing fesoterodine or a pharmaceutically acceptable salt thereof in high purity.Type: ApplicationFiled: November 18, 2010Publication date: May 26, 2011Applicant: ACTAVIS GROUP PTC EHFInventors: Kishore CHARUGUNDLA, Udhaya KUMAR, Neela Praveen KUMAR, Nitin Sharadchandra PRADHAN
-
Patent number: 7947699Abstract: Described is a highly stable amorphous form of imatinib mesylate having a water content of less than 0.5 percent by weight, based on the total weight of the amorphous imatinib mesylate, (anhydrous amorphous imatinib mesylate), a process for preparation thereof, and pharmaceutical compositions.Type: GrantFiled: January 9, 2009Date of Patent: May 24, 2011Assignee: Actavis Group PTC EHFInventors: Mayur Devjibhai Khunt, Nilesh Sudhir Patil, Haushabhau Shivaji Pagire, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Publication number: 20110117200Abstract: Provided herein is rasagiline mesylate having a 90 volume-percent of the particles (D90) with a size of about 600 microns to about 1500 microns, and a process for the preparation thereof. Provided also herein are pharmaceutical compositions comprising rasagiline mesylate particles having a particle size which is suitable for homogeneous distribution of the drug substance in a tablet blend, in particular 90 volume-percent of the particles (D90) have a size of about 255 microns to about 1500 microns, and a process the preparation thereof.Type: ApplicationFiled: March 31, 2009Publication date: May 19, 2011Applicant: ACTAVIS GROUP PTC EHFInventors: Nilesh Sudhir Patil, Haushabhau Shivaji Pagire, Praveen Kumar Neela, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Publication number: 20110105756Abstract: Disclosed herein is an improved, commercially viable and industrially advantageous process for the preparation of quinoline-3-carboxamide derivatives such as laquinimod, or a pharmaceutically acceptable salt thereof, in high yield and purity.Type: ApplicationFiled: April 27, 2009Publication date: May 5, 2011Applicant: ACTAVIS GROUP PTC EHFInventors: Girish Dixit, Krishnadatt Sharma, Kundan Singh Shekhawat, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Publication number: 20110097413Abstract: Provided herein are novel solid state forms of deferasirox salts, process for the preparation, pharmaceutical compositions, and method of treating thereof. The solid state forms of deferasirox salts are useful for preparing deferasirox (I) in high purity.Type: ApplicationFiled: April 20, 2009Publication date: April 28, 2011Applicant: ACTAVIS GROUP PTC EHFInventors: Praveen Kumar Neela, Kishore Charugundla, Rajendra Suryabhan Patil, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Publication number: 20110086103Abstract: Provided herein is a novel raantlelate sail of fesoterodine, process for the preparation, pharmaceutics!! compositions, and method of treating thereof. Provided also herein are solid state forms of fesoterodine mandelate, process for the preparation, pharmaceutical compositions, and method of treating thereof. The raandelate salt of fesoterodine is useful for preparing fesoterodine free base or a pharmaceutically acceptable salt thereof; particularly fesoterodine fumaraie, in high purity.Type: ApplicationFiled: April 6, 2009Publication date: April 14, 2011Applicant: ACTAVIS GROUP PTC EHFInventors: Kishore Charugundla, Udhaya Kumar, Praveen Kumar Neela, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Publication number: 20110071120Abstract: Provided herein are novel solid state forms of tapentadol salts, process for their preparation, pharmaceutical compositions, and method of treating thereof. The tapentadol salts include an L-(?)-camphorsulfonate salt, a dibenzoyl-(L)-tartrate salt, a dibenzoyl-(D)-tartrate salt, a malate salt, a maleate salt, or a salicylate salt.Type: ApplicationFiled: September 21, 2010Publication date: March 24, 2011Applicant: ACTAVIS GROUP PTC EHFInventors: Mayur Devjibhai Khunt, Sandipan Prabhurao Bondge, Vikas Daulatrao Ahirao, Depashri Vikas Ahirao, Nitin Sharadchandra Pradhan
-
Publication number: 20110046231Abstract: The present invention relates to solid forms of (±)-O-desmethylvenlafaxine salts, processes for preparation, pharmaceutical compositions, and method of treating thereof. More particularly, the present invention provides solid forms of acid addition salts of (±)-O-desmethylvenlafaxine wherein the acid counter ion is provided by an acid selected from the group consisting of oxalic acid, benzoic acid and lactic acid.Type: ApplicationFiled: October 21, 2008Publication date: February 24, 2011Applicant: ACTAVIS GROUP PTC EHFInventors: Sonny Sebastian, Raman Buddhavarapu Pattabhi, Krishna Challa, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Publication number: 20110021547Abstract: Described is a highly stable crystalline form of bosentan having a water content in the range of about 3-4% by weight, based on the total weight of the bosentan, (bosentan crystalline form A5), a process for preparation thereof, and pharmaceutical compositions comprising the bosentan crystalline form A5. Provided also herein is a bosentan impurity, p-tert-butyl-N[6-hydroxy-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide (deshydroxyethyl bosentan impurity), and process for preparing and isolating thereof. Further provided are highly pure bosentan or a pharmaceutically acceptable salt thereof substantially free of deshydroxyethyl bosentan and bosentan dimer impurities, process for the preparation thereof, and pharmaceutical compositions comprising solid particles of highly pure bosentan or a pharmaceutically acceptable salt thereof, wherein 90 volume-percent of the particles (D90) have a size of less than about 300 microns.Type: ApplicationFiled: January 22, 2009Publication date: January 27, 2011Applicant: ACTAVIS GROUP PTC EHFInventors: Girish Dixit, Nandkumar Gaikwad, Hima Prasad Naidu, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Publication number: 20110014246Abstract: Disclosed herein is a novel and stable amorphous form of arformoterol L-(+)-tartrate, a process for its preparation, pharmaceutical compositions comprising amorphous arformoterol L-(+)-tartrate, and methods of treating with amorphous arformoterol L-(+)-tartrade.Type: ApplicationFiled: February 27, 2009Publication date: January 20, 2011Applicant: ACTAVIS GROUP PTC EHFInventors: Girish Dixit, Nandkumar Gaikwad, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Publication number: 20110014291Abstract: Disclosed herein are novel polymorphic forms of bosentan, processes for preparation, pharmaceutical compositions, and method of treating thereof.Type: ApplicationFiled: October 13, 2008Publication date: January 20, 2011Applicant: ACTAVIS GROUP PTC EHFInventors: Girish Dixit, Nandkumar Gaikwad, Hima Prasad Naidu, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Publication number: 20100330130Abstract: Provided herein are impurities of imatinib, N-(2-Methyl-5-methylamino-phenyl)-N-(4-pyridin-3-yl-pyrimidin-2-yl)-formamide (formamide impurity) and 4-[4-(Imidazole-1-carbonyl)-piperazin-1-ylmethyl]-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide (carbonylimidazole impurity), and processes for the preparation and isolation thereof. Provided further herein is a highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of formamide and carbonylimidazole impurities, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of impurities. Disclosed also herein is a process for preparing substantially pure ?-form of imatinib mesylate.Type: ApplicationFiled: May 18, 2010Publication date: December 30, 2010Applicant: ACTAVIS GROUP PTC EHFInventors: Mayur Devjibhai KHUNT, Nilesh Sudhir PATIL, Haushabhau Shivaji PAGIRE, Nitin Sharadchandra PRADHAN
-
Publication number: 20100317859Abstract: Disclosed herein is an improved, commercially viable and industrially advantageous process for the preparation of risedronic acid or a pharmaceutically acceptable salt thereof, in high yield and purity.Type: ApplicationFiled: May 16, 2008Publication date: December 16, 2010Applicant: ACTAVIS GROUP PTC EHFInventors: Neela Praveen Kumar, Dnyaneshwar Singare, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Publication number: 20100297241Abstract: The present invention provides a novel amorphous form of fesoterodine fumarate, process for preparation, pharmaceutical compositions, and method of treating thereof.Type: ApplicationFiled: October 1, 2008Publication date: November 25, 2010Applicant: ACTAVIS GROUP PTC EHFInventors: Kishore Charugundla, Udhaya Kumar Chandramohan, Nitin Sharadchandra Pradhan, Jon Valgeirsson, Praveen Kumar Neela
-
Publication number: 20100285075Abstract: The present invention relates to novel hemioxalate salt of eletriptan, process for preparation, pharmaceutical compositions, and method of treating thereof. The present invention relates to solid forms of eletriptan hemioxalate, processes for preparation, pharmaceutical compositions, and method of treating thereof. The solid form of eletriptan hemioxalate is useful for preparing eletriptan free base or a pharmaceutically acceptable salt thereof, particularly eletriptan hydrobromide, in high purity. The present invention also provides a process for preparing substantially pure eletriptan hydrobromide using eletriptan hemioxalate.Type: ApplicationFiled: December 17, 2008Publication date: November 11, 2010Applicant: ACTAVIS GROUP PTC EHFInventors: Vijaya Gopal Kusumba, Sampath Kumar Sankineni, Praveen Kumar Neela, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Publication number: 20100278878Abstract: The present invention relates to novel and stable salt forms of quetiapine, processes for preparation, pharmaceutical compositions, and method of treating thereof. More particularly, the present invention provides novel acid addition salts of quetiapine wherein the acid counter ion is provided by an acid selected from the group consisting of benzene sulfonic acid, dibenzoyl-L-(+)-tartaric acid and di-p-toluoyl-L-(+)-tartaric acid. The present invention also provides novel polymorphic forms of quetiapine salts selected from the group consisting of quetiapine hydrobromide, quetiapine sulfate, quetiapine nitrate and quetiapine citrate.Type: ApplicationFiled: May 7, 2008Publication date: November 4, 2010Applicant: ACTAVIS GROUP PTC EHFInventors: Girish Dixit, Anil Shahaji Khile, Jayesh Laljibhai Patel, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Publication number: 20100260851Abstract: The present invention provides a novel polymorphic form of atorvastatin calcium, designated as form Al, process for preparation, pharmaceutical compositions, and method of treating thereof. The present invention further provides a process for the preparation of highly pure amorphous atorvastatin calcium using the novel atorvastatin calcium form Al. The present invention also relates to novel amorphous form of atorvastatin tert-butyl ester, chemically known as [R-(R*,R*)]-2-(4-fluorophenyl)-[?],[?]-dihydroxy -5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl-1H-pyrrole-1-heptanoicacid tert-butyl ester, process for the preparation, and its application for preparing highly pure atorvastatin and its pharmaceutically acceptable salts thereof. The present invention also relates to use of the novel amorphous atorvastatin tert-butyl ester and novel atorvastatin calcium form al for preparing amorphous atorvastatin calcium.Type: ApplicationFiled: July 11, 2008Publication date: October 14, 2010Applicant: ACTAVIS GROUP PTC EHFInventors: Girish Dixit, Anil Shahaji Khile, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Publication number: 20100217034Abstract: Disclosed herein is an improved, commercially viable and industrially advantageous process for the preparation of Fesoterodine or a pharmaceutically acceptable salt thereof in high yield and purity. Disclosed also herein is an improved and industrially advantageous optical resolution method of racemic (±)-N,N-Diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropylamine and use thereof for the preparation of Fesoterodine.Type: ApplicationFiled: September 22, 2008Publication date: August 26, 2010Applicant: ACTAVIS GROUP PTC EHFInventors: Kishore Charugundla, Udhaya Kumar, Rajendra Suryabhan Patil, Praveen Kumar Neela, Nitin Sharadchandra Pradhan, Jon Valgeirsson